Literature DB >> 18675848

CD83 on murine APC does not function as a costimulatory receptor for T cells.

Birte Kretschmer1, Katja Lüthje, Svenja Ehrlich, Anke Osterloh, Melanie Piedavent, Bernhard Fleischer, Minka Breloer.   

Abstract

The transmembrane glycoprotein CD83 is rapidly upregulated on murine and human DC upon maturation and therefore a costimulatory function for T cell activation has been suggested. Studies employing human APC indeed showed that CD83 expression was positively correlated to the stimulatory capacity of the APC. Murine APC that were CD83 deficient however, did not display a reduced capacity to activate T cells. To elucidate this contradiction, we thoroughly compared the stimulatory capacity of CD83-overexpressing and CD83-deficient APC. Here we show that CD83 expression levels on APC did not affect the capacity of the APC to activate CD8(+) T cells. CD83 expression levels did not significantly affect CD4(+) T cell activation in vivo, but a weak positive correlation of CD83 expression with CD4(+) T cell activation was observed in vitro under suboptimal stimulation conditions. As CD83 expression also positively correlated with MHC-II but not with MHC-I expression, this differential stimulation specifically of CD4(+) T cells could be explained by a higher density of MHC-II peptide complexes on the APC surface. Taken together, our results strongly suggest that CD83 does not deliver crucial costimulatory signals to murine T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18675848     DOI: 10.1016/j.imlet.2008.07.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2.

Authors:  Liwen Chen; Yibei Zhu; Guangbo Zhang; Chao Gao; Weixue Zhong; Xueguang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 2.  ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.

Authors:  Klaus Ley; Norbert Gerdes; Holger Winkels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-30       Impact factor: 8.311

3.  CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation.

Authors:  Lina E Tze; Keisuke Horikawa; Heather Domaschenz; Debbie R Howard; Carla M Roots; Robert J Rigby; David A Way; Mari Ohmura-Hoshino; Satoshi Ishido; Christopher E Andoniou; Mariapia A Degli-Esposti; Christopher C Goodnow
Journal:  J Exp Med       Date:  2011-01-10       Impact factor: 14.307

4.  CD83 orchestrates immunity toward self and non-self in dendritic cells.

Authors:  Andreas B Wild; Lena Krzyzak; Katrin Peckert; Lena Stich; Christine Kuhnt; Alina Butterhof; Christine Seitz; Jochen Mattner; Niklas Grüner; Maximilian Gänsbauer; Martin Purtak; Didier Soulat; Thomas H Winkler; Lars Nitschke; Elisabeth Zinser; Alexander Steinkasserer
Journal:  JCI Insight       Date:  2019-10-17

5.  Continuous expression of CD83 on activated human CD4⁺ T cells is correlated with their differentiation into induced regulatory T cells.

Authors:  Liwen Chen; Shihe Guan; Qiang Zhou; Shouqin Sheng; Fei Zhong; Qin Wang
Journal:  Mol Med Rep       Date:  2015-05-18       Impact factor: 2.952

6.  Targeting CD83 for the treatment of graft-versus-host disease.

Authors:  Xiongfei Wang; Ming Q Wei; Xiaosong Liu
Journal:  Exp Ther Med       Date:  2013-04-02       Impact factor: 2.447

Review 7.  The CD83 Molecule - An Important Immune Checkpoint.

Authors:  Linda Grosche; Ilka Knippertz; Christina König; Dmytro Royzman; Andreas B Wild; Elisabeth Zinser; Heinrich Sticht; Yves A Muller; Alexander Steinkasserer; Matthias Lechmann
Journal:  Front Immunol       Date:  2020-04-17       Impact factor: 7.561

Review 8.  Tilting the Balance: Therapeutic Prospects of CD83 as a Checkpoint Molecule Controlling Resolution of Inflammation.

Authors:  Katrin Peckert-Maier; Dmytro Royzman; Pia Langguth; Anita Marosan; Astrid Strack; Atefeh Sadeghi Shermeh; Alexander Steinkasserer; Elisabeth Zinser; Andreas B Wild
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.